

13 June 2024

Physiomics plc
("Physiomics" or the "Company")

Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a new contract by an existing, large client. The project involves the use of our proprietary Virtual Tumour platform to model the client's targeted oncology agents in combination with other modalities to help inform dose and scheduling decisions. The value of the contract is £186k and it is anticipated that it will be completed over the course of the current calendar year. This project and associated contract award is the second of the two referred to in the Company's trading update on 3 May 2024 and now means that the Company will be going into its next financial year ending 30 June 2025 with committed revenues of over £0.5m.

Dr Peter Sargent, CEO, commented: *"After many months of discussion and negotiation with the client, I'm delighted that we can now start this substantial project. This win reflects the significant experience and expertise the Physiomics team has built up over the years, in particular around more complex modelling of combination therapies".*

Enquiries:

Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTEAXKAFSXLEFA